STAT+: Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
The FDA will convene a meeting of independent advisers to review a personalized cell therapy for ALS that the agency has previously refused to consider.
The Food and Drug Administration will convene a meeting of independent advisers to review a personalized cell therapy for ALS that the agency has previously refused to consider.
On Monday, BrainStorm Cell Therapeutics, maker of the experimental ALS treatment called NurOwn, said the FDA had agreed to hold an advisory committee meeting. A date has not been set. An FDA spokesperson declined to comment.
What's Your Reaction?
